Drug Database
BE

benzodiazepine

✓ Approved

Valenta Pharm · Small Molecule · Small Molecule

What is benzodiazepine?

benzodiazepine is a small molecule developed by Valenta Pharm. It is approved for therapeutic indications via oral (po).

Drug Profile

CompanyValenta Pharm
Drug ClassSmall Molecule
RouteOral (PO)
StatusApproved

Therapeutic Indications

benzodiazepine is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Psychiatric disordersAnxiety✓ Approved

Related Research Articles

PubMedNeuroscience2026-07-24

Diazepam reduces hippocampal and behavioral plasticity, blunting environmental impact on emotional responses.

Poggini Silvia S, Veleanu Maxime M, Albanese Naomi Ciano NC, Bronnec Martin M et al.

Plasticity is essential for mental health, as it enables individuals to adapt to environmental changes. However, its effects are highly context-dependent. While increased plasticity can be beneficial in supportive environments, as treatments that enhance plasticity have proved more effective when paired with favorable experiences, it may promote maladaptive responses under adverse conditions. Accordingly, a reduction in plasticity is expected to be beneficial in adverse circumstances, as it can limit harmful influences on mental well-being. To test this hypothesis, we investigated whether diazepam, a benzodiazepine that reduces neural plasticity, thereby attenuates the impact of environmental conditions on behavioral and physiological endophenotypes of depression. In a first experiment, we treated C57BL/6 adult male and female mice with diazepam or vehicle, delivered either orally or intraperitoneally, and found a consistent impairment in synaptic plasticity, as indicated by reduced hippocampal long-term potentiation. In a second experiment, after inducing a depression-like phenotype, we treated C57BL/6 adult male mice for three weeks with diazepam or vehicle in either enriched or stressful conditions. The treatment had opposite effects depending on the environmental conditions. In enrichment, it was associated with no significant recovery from anhedonia, whereas under stress, it prevented a further worsening, relative to the control groups. Diazepam also affected anxiety-related behavioral outcomes and hypothalamic-pituitary-adrenal axis activation in an environment-dependent manner. Overall, we demonstrate that diazepam, impairing hippocampal plasticity, blunts the impact of environmental factors on the behavioral outcome. These findings underscore the potential of tailoring neural plasticity to environmental quality as a strategy in precision psychiatry.

PubMedSante mentale au Quebec2026-07-23

[Cooccurrence of catatonia, delirium and dementia in an elderly woman: A case report].

Cossette-Lefebvre Maude M, Bergeron Nicolas N

Catatonia is a severe but underrecognized neuropsychiatric syndrome that is frequently misdiagnosed as delirium or dementia in older adults, resulting in delayed and potentially inappropriate treatment. A 79-year-old woman was admitted for rapid cognitive decline, significant weight loss, and social withdrawal. Initial evaluations suggested major depressive disorder or dementia. Neurological investigations were inconclusive. Following the initiation of psychotropic medication, psychiatric assessment revealed mutism, posturing, and marked psychomotor retardation, fulfilling DSM-5 criteria for catatonia. A lorazepam challenge test confirmed the diagnosis. Psychotropic medications were discontinued, and lorazepam was titrated to 2 mg 4 times daily, resulting in significant clinical improvement. Subsequent brain positron emission tomography (PET) imaging along with clinical evidence supported the presence of an underlying Alzheimer's disease. However, the emergence of superimposed delirium required gradual benzodiazepine tapering. Memantine was subsequently introduced, allowing lorazepam withdrawal and full symptomatic remission. The patient was discharged home. During outpatient follow-up, recurrence of partial symptoms prompted consideration of alternative therapeutic strategies. This case underscores the importance of recognizing catatonia in older adults presenting with cognitive impairment. It highlights the diagnostic and therapeutic challenges posed by the coexistence of catatonia, delirium, and neurodegenerative disease, and emphasizes the need for early identification and a multidisciplinary approach to optimize outcomes.

PubMedTalanta2026-07-23

Hybrid multispectroscopic-chemometric strategy combined with DLLME for the detection of benzodiazepines in complex beverage matrices.

Emanetoglu Busra B, Guzel Pelin P, Koyuncu Elif E, Bayar Fatma Nur FN et al.

The detection of benzodiazepines in beverage residues is of crucial importance in forensic toxicology, particularly in investigations of drug-facilitated crimes. However, their determination in complex beverage matrices remains analytically challenging by severe matrix interferences and low analyte concentrations. In this study, a hybrid multispectroscopic-chemometric methodology was developed for determination of alprazolam (ALP) and lorazepam (LORA) following dispersive liquid-liquid microextraction (DLLME) pretreatment. The proposed approach integrates DLLME with UV-Vis, fluorescence and their derivative spectroscopies, combined with principal component analysis (PCA) and correlation-based data evaluation. Various beverage matrices, including wine, vodka, soft drinks, and sparkling water, were analyzed to assess the method's applicability under realistic forensic scenarios. DLLME significantly enhanced spectral quality and minimized matrix effects, improving the detection of both analytes in various beverages. UV-Vis derivative spectroscopy enhanced spectral resolution with analyte-dependent performance, while fluorescence spectroscopy provided complementary analytical information. Chemometric interpretation via principal component analysis (PCA) enabled effective differentiation between blank and spiked samples, confirming the robustness and reliability of the proposed analytical workflow. For both ALP and LORA cases, the first three principal components cumulatively captured over 80% of the total variance, indicating that they were statistically sufficient to adequately represent the dataset for further data analysis. Cluster validation using the elbow and silhouette methods consistently supported k = 2 as the optimal number of clusters for both cases. Overall, the combined DLLME-multispectroscopic-chemometric strategy offers a rapid, cost-effective, and accessible alternative to advanced instrumental techniques for the preliminary screening and differentiation of benzodiazepine residues in complex forensic beverage samples.

PubMedOrganic letters2026-07-22

Ru(II)-Catalyzed C-H Sulfonamidation of the Medicinally Relevant Benzodiazepine Scaffolds.

Rav Shourabh S, Gupta Shiv Shankar SS, Sarthi, Hassell-Hart Storm S et al.

A late-stage, efficient C-H functionalization of medicinally relevant 1,4-benzodiazepines for direct C-H sulfonamidation has been developed via Ru-catalyzed C-H activation. Tosyl azide (TsN3) serves as a bench-stable sulfonamidating reagent. The sulfonamidated product is further converted to an aminated product through chemoselective hydrolysis of the sulfonamide bond. In mechanistic studies, a ruthenacycle (BDZ-Ru-Cl) has been synthesized and characterized by NMR spectroscopy and SC-XRD. Additionally, a novel intermediate, Int-C (a six-membered N-SO2Ar-inserted species), was synthesized from BDZ-Ru-Cl, providing further support for the proposed mechanistic pathway. Density functional theory (DFT) studies were also conducted to gain deeper mechanistic insight and to validate the developed protocol.

PubMedSubstance abuse treatment, prevention, and policy2026-07-21

Managing benzodiazepine dependence arising from use of the adulterated opioid supply: a commentary.

Parmar Gurkiran G, Malette Nicole N, Ross Josey J, Crabtree Alexis A et al.

The growing presence of benzodiazepine-adulterated opioids in the unregulated drug supply poses significant challenges for clinicians treating people with opioid use disorder. This commentary highlights key areas of uncertainty and emerging agreement on screening, risk assessment, withdrawal timelines, and treatment approaches for individuals using benzodiazepine-adulterated opioids. It also identifies gaps in community-based support, the effectiveness of drug checking, and the role of medications for opioid use disorder in managing opioid-benzodiazepine withdrawal. Together, these scenarios demonstrate rapidly evolving challenges and the need to refine clinical practices in order to improve care for individuals affected by the evolving unregulated drug supply.

PubMedNeuropsychopharmacology reports2026-07-21

The "GABAergic Brake" on the Spinal Defecation Reflex: A Proposed Neurobiological Model Explaining Clozapine- and Benzodiazepine-Induced Gastrointestinal Hypomotility and Ogilvie's Syndrome.

Nagamine Takahiko T

Synergistic "Double Brake" Model on the Spinal Defecation Center in Clozapine-Induced Constipation. Real-world data shows BZDRs increase laxative risk in schizophrenia. Mitigating the central GABAergic brake via sedative optimization and maintaining gut microbiota homeostasis prevents fatal Ogilvie's syndrome.

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about benzodiazepine